Sentences with phrase «brand drug manufacturers»

Brand drug manufacturers might welcome Amazon, at least initially, as an additional channel to reach consumers.

Not exact matches

The world's largest drug manufacturer is facing steep competition from a slew of smaller generic players, and the recent loss of patent protection on its major branded drug, Copaxone, is threatening Teva's profit margins.

Some manufacturers have recently boosted discounts as insurers and benefits managers have excluded more - expensive brands from lists of covered drugs.

For a generic drug manufacturer to get the U.S. Food and Drug Administration's (FDA) stamp of approval, they must prove it is pharmaceutically equal to the name - brand versdrug manufacturer to get the U.S. Food and Drug Administration's (FDA) stamp of approval, they must prove it is pharmaceutically equal to the name - brand versDrug Administration's (FDA) stamp of approval, they must prove it is pharmaceutically equal to the name - brand version.

Private Label Manufacturers Association — Labeling and Packaging Members represent small to large manufacturers of food and non-food products sold under store brands and private label brands in supermarkets, drug stores, mass merchandisers or specialManufacturers Association — Labeling and Packaging Members represent small to large manufacturers of food and non-food products sold under store brands and private label brands in supermarkets, drug stores, mass merchandisers or specialmanufacturers of food and non-food products sold under store brands and private label brands in supermarkets, drug stores, mass merchandisers or specialty retailers.

Professionals from retailers, brand owners or manufacturers of consumer goods, such as processed foods, beverages, toiletries, over-the-counter drugs, toys, etc..

There is significant regulatory risk afoot for some Australian infant formula brands as they await approval from the China Food and Drug Administration ahead of new regulations starting on January 1 for all manufacturers of formula products sold into China from around the world.

* Eliminate «pay - for - delay» strategies in which a pharmaceutical company with a brand name drug shares profits on that drug with a generic drug manufacturer for the remainder of a patent period, effectively eliminating a patent challenge and competition.

Even the drug's manufacturer (to whom you should immediately report the reaction — giving them the brand and lot # — may deny the connection.

«Joint supplements are popular because they enable a consumer to provide relief for their arthritic dog at a fraction of the cost of currently available drugs and without all the possible side effects,» explains Sinead Imbaro, president of Olympic Olympic Brands, Inc., a Miami, Fla. - based manufacturer of NutriFlex brand joint supplements.

Once a patent expires, other manufacturers can create generic drugs but must scientifically prove that their medications perform in the same way as the branded drug to get FDA approval.

Still, the U.S. made the data exclusivity period so long, it drove at least one manufacturer to treat a biosimilar as a brand new drug and submit to the full FDA approval process.

The manufacturers are said to have used the KOLs for «unbranded» marketing, thereby evading the strictures of branded marketing, which is closely supervised by the U.S. Food and Drug Administration.

On an issue of first impression, however, the California Court of Appeals in Conte v. Wyeth, Inc. rejected this traditional view and held that a brand - name manufacturer's duty to warn extends to patients whose prescriptions are filled with the generic version of the drug.

Following the decision, three other courts adopted this minority position that brand - name manufacturers can be liable for injuries caused by the generic version of their drug.

Early last year, the Alabama Supreme Court ruled that a patient could sue a brand - name manufacturer for not warning about a drug's risks even if the medication involved is a generic version made by another company.

In cases involving the Hatch - Waxman Act and issues involving the expiration of pharmaceutical patents and competition between branded drug companies and generic manufacturers, our antitrust litigation graphics can illuminate a complicated industry and a complex regulatory scheme as below:

Pay - for - delay («PFD») agreements are agreements that are intended to delay the market entry of generic manufacturers with generic drugs in exchange for payments made by original pharmaceutical producers (i.e., holders of patents for an original branded drug).

New California Appellate Decision Makes Brand Name Drug Manufacturers Potentially Liable for Injuries Suffered by Consumers of Generic Drugs

Plaintiff May Sue Manufacturer of Name - Brand Prescription Drug for Injury Allegedly Caused by Different Company's Generic Drug, Indiana Injury Lawyer Blog, February 28, 2013 Federal Statute Preempts State Products Liability Lawsuit Over Asbestos Exposure, According to Supreme Court: Kurns v. Railroad Friction Products Corp., Indiana Injury Lawyer Blog, October 18, 2012

That's because the warning and usage labels are created by the brand name manufacturer, but because brand name manufacturers aren't the ones making the drugs at issue, many courts have held they can not be liable.

Corp. [2] unanimously recognized the doctrine holding that brand - name prescription drug manufacturers owe a duty to warn to consumers who use generic drugs.

[9] The potential lifelong side effects of this drug were not disclosed within the brand - name manufacturer's nor the mirrored generic manufacturer's warning label.

The court's concern that redress be available to those who ingest generic drugs by establishing liability to the controlling brand - name manufacturer carried the day.

[16] The SJC considered innovator liability to require such a modification given the certainty that a user of a generic drug will rely on the label fashioned by the brand - name manufacturer and as state law shields failure to warn claims from generic manufacturers, leaving plaintiffs without recourse for their injuries.

Specifically, in Rafferty v. Merck & Co., Inc., [4] the SJC held that plaintiffs who ingest the generic form of a drug may bring failure to warn claims against the brand - name manufacturer of the drug if the brand - name defendant acted recklessly by «intentionally fail [ing] to update the label on its drug while knowing or having reason to know of an unreasonable risk of death or grave bodily injury associated with its use.»

Balancing these competing interests, the court held that, «a brand - name manufacturer that controls the contents of the label on a generic drug owes a duty to consumers of that generic drug not to act in reckless disregard of an unreasonable risk of death or grave bodily injury.»

Relevant to the matter considered by the SJC, the Drug Price Competition and Patent Term Restoration Act, informally known as the «Hatch - Waxman Act» requires the «manufacturer of a generic drug [to] provide its users with a warning label that is identical to the label of the brand - name counterpart.&raDrug Price Competition and Patent Term Restoration Act, informally known as the «Hatch - Waxman Act» requires the «manufacturer of a generic drug [to] provide its users with a warning label that is identical to the label of the brand - name counterpart.&radrug [to] provide its users with a warning label that is identical to the label of the brand - name counterpart.»

Mr. Simon also recently represented a generic brand drug company in an individual case alleging that the brand name manufacturer had filed false citizens petitions to delay the entry of the generic drug unto the market.

Per that law, generic drugs must be designed the same as their brand counterparts and come with the same labels and Mutual and other generic medical manufacturers have said that because they have to be designed and labeled exactly as their brand equivalents, it is not up to them to modify a generic drug's design or labeling.

Now, the justices are trying to decide whether generic drug manufacturers can be sued in state court for design defects - especially when the generic version is an exact copy of its brand - name counterpart that the federal government had already approved.

[10] Prior to 2006, the price at which manufacturers could apply to list generic drugs in the Formulary was capped by regulations under the Actsat effectively 63 % of the price of the brand - name drug.

«Any recognition of an outlier theory of liability permitting a generic drug consumer to bring an action against the brand manufacturer for an injury allegedly arising from the use of the generic drug would be plainly at odds with this public policy.»

With generic drugs, it is not merely foreseeable but certain that the warning label provided by the brand - name manufacturer will be identical to the warning label provided by the generic manufacturer, and moreover that it will be relied on, not only by users of its own product, but also by users of the generic product.

Prescription drugs that are no longer patent - protected and are sold by drug manufacturers under a different name than the original brand name drug.

Thermafreeze (Red Bank, NJ) 09/2009 — 11/2010 National Sales Manager • Designed and implemented a comprehensive sales and marketing strategy for a retail manufacturer of alternative ice products • Successfully led the conversion from a commercial manufacturer to a retail manufacturer • Established a national tier 1 independent broker network resulting in significantly enhanced corporate reach and revenues • Trained brokers and salespeople in sales and marketing best practices, presentation techniques, and product information • Organized national tradeshows to introduce ThermaFreeze to supermarkets, mass merchandisers, and the drug store industry • Devised and successfully executed strategies for product image, branding, packaging, retail displays, and shipping